Eiger Biopharmaceuticals (NASDAQ:EIGR) had its price target decreased by Wedbush from $36.00 to $34.00 in a research report report published on Thursday morning. Wedbush currently has an outperform rating on the biotechnology company’s stock.
Several other brokerages have also recently commented on EIGR. Oppenheimer set a $34.00 target price on shares of Eiger Biopharmaceuticals and gave the stock a buy rating in a report on Thursday, December 7th. ValuEngine cut shares of Eiger Biopharmaceuticals from a sell rating to a strong sell rating in a report on Thursday, March 1st. Zacks Investment Research cut shares of Eiger Biopharmaceuticals from a buy rating to a hold rating in a report on Tuesday, February 20th. Ladenburg Thalmann Financial Services initiated coverage on shares of Eiger Biopharmaceuticals in a report on Wednesday, January 3rd. They issued a buy rating and a $32.00 target price for the company. Finally, Piper Jaffray Companies reiterated an overweight rating and issued a $17.00 target price (down from $35.00) on shares of Eiger Biopharmaceuticals in a report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. Eiger Biopharmaceuticals currently has an average rating of Buy and a consensus target price of $27.25.
Eiger Biopharmaceuticals stock opened at $10.10 on Thursday. Eiger Biopharmaceuticals has a fifty-two week low of $6.10 and a fifty-two week high of $16.20. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.58.
Several hedge funds have recently bought and sold shares of EIGR. Prosight Management LP acquired a new stake in shares of Eiger Biopharmaceuticals during the fourth quarter worth approximately $9,469,000. Jennison Associates LLC acquired a new stake in shares of Eiger Biopharmaceuticals during the fourth quarter worth approximately $8,430,000. Armistice Capital LLC acquired a new stake in shares of Eiger Biopharmaceuticals during the fourth quarter worth approximately $5,357,000. Stonepine Capital Management LLC acquired a new stake in shares of Eiger Biopharmaceuticals during the fourth quarter worth approximately $2,093,000. Finally, Sphera Funds Management LTD. boosted its holdings in shares of Eiger Biopharmaceuticals by 35.0% during the third quarter. Sphera Funds Management LTD. now owns 520,269 shares of the biotechnology company’s stock worth $5,723,000 after purchasing an additional 134,968 shares during the period. Institutional investors and hedge funds own 68.96% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3301581/eiger-biopharmaceuticals-eigr-price-target-cut-to-34-00.html.
About Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.